Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Research

Small airways morphological alterations associated with functional impairment in lymphangioleiomyomatosis

Authors: Lígia Pelosi Mendonça, Natalia de Souza Xavier Costa, Ellen Caroline Toledo do Nascimento, Martina Rodrigues de Oliveira, Carlos Roberto Ribeiro de Carvalho, Bruno Guedes Baldi, Marisa Dolhnikoff

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Lymphangioleiomyomatosis (LAM) is a rare neoplastic and cystic pulmonary disease characterized by abnormal proliferation of the so-called LAM cells. Despite the functional obstructive pattern observed in most patients, few studies investigated the morphological changes in the small airways, most of them in patients with severe and advanced LAM undergoing lung transplantation. Understanding the morphological changes in the airways that may occur early in the disease can help us understand the pathophysiology of disease progression and understand the rationale for possible therapeutic approaches, such as the use of bronchodilators. Our study aimed to characterize the morphological alterations of the small airways in patients with LAM with different severities compared to controls, and their association with variables at the pulmonary function test and with LAM Histological Score (LHS).

Methods

Thirty-nine women with LAM who had undergone open lung biopsy or lung transplantation, and nine controls were evaluated. The histological severity of the disease was assessed as LHS, based on the percentage of tissue involvement by cysts and infiltration by LAM cells. The following morphometric parameters were obtained: airway thickness, airway closure index, collagen and airway smooth muscle content, airway epithelial TGF-β expression, and infiltration of LAM cells and inflammatory cells within the small airway walls.

Results

The age of patients with LAM was 39 ± 8 years, with FEV1 and DLCO of 62 ± 30% predicted and 62 ± 32% predicted, respectively. Patients with LAM had increased small airway closure index, collagen and smooth muscle content, and epithelial TGF-beta expression compared with controls. Patients with LAM with the more severe LHS and with greater functional severity (FEV1 ≤ 30%) presented higher thicknesses of the airways. Bronchiolar inflammation was mild; infiltration of the small airway walls by LAM cells was rare. LHS was associated with an obstructive pattern, air trapping, and reduced DLCO, whereas small airway wall thickness was associated with FEV1, FVC, and collagen content.

Conclusion

LAM is associated with small airway remodelling and partial airway closure, with structural alterations observed at different airway compartments. Functional impairment in LAM is associated with airway remodelling and, most importantly, with histological severity (LHS).
Literature
2.
go back to reference Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001;164(8):1537–40.CrossRefPubMed Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001;164(8):1537–40.CrossRefPubMed
3.
go back to reference Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. Q J Med. 2011;104(11):971–9.CrossRef Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. Q J Med. 2011;104(11):971–9.CrossRef
4.
go back to reference Junior PM, Carvalho CRR. Linfangioleiomiomatose pulmonar. J Bras Pneumol. 2004;30(1):66–77.CrossRef Junior PM, Carvalho CRR. Linfangioleiomiomatose pulmonar. J Bras Pneumol. 2004;30(1):66–77.CrossRef
5.
go back to reference Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013;144(2):578–85.CrossRefPubMed Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013;144(2):578–85.CrossRefPubMed
6.
go back to reference Aubry MC, Myers JL, Ryn JH, Henske EP, Logginidou H, Jalal SM, et al. Pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2000;162:749–52.CrossRefPubMed Aubry MC, Myers JL, Ryn JH, Henske EP, Logginidou H, Jalal SM, et al. Pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2000;162:749–52.CrossRefPubMed
7.
go back to reference Taylor JR, Ryu J, Colby T, et al. Lymphangioleiomyomatosis: clinical course in 32 patients. N Engl J Med. 1990;323:1254–60.CrossRefPubMed Taylor JR, Ryu J, Colby T, et al. Lymphangioleiomyomatosis: clinical course in 32 patients. N Engl J Med. 1990;323:1254–60.CrossRefPubMed
9.
go back to reference Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and Disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004;59(9):800–3.CrossRefPubMedPubMedCentral Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and Disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004;59(9):800–3.CrossRefPubMedPubMedCentral
11.
go back to reference Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangioleiomyomatosis Registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173(1):105–11.CrossRefPubMed Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangioleiomyomatosis Registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173(1):105–11.CrossRefPubMed
13.
go back to reference Oprescu N, Mccormack FX, Byrnes S, et al. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung. 2013;191(1):35–42.CrossRefPubMed Oprescu N, Mccormack FX, Byrnes S, et al. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung. 2013;191(1):35–42.CrossRefPubMed
14.
go back to reference Taveira-dasilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol. 2010;8(1):9–19.CrossRefPubMedPubMedCentral Taveira-dasilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol. 2010;8(1):9–19.CrossRefPubMedPubMedCentral
15.
go back to reference Baldi BG, Freitas CSG, Araujo MS, Dias OM, Pereira DAS, Pimenta SP, Kairalla RA, Carvalho CRR. Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):129–35.PubMed Baldi BG, Freitas CSG, Araujo MS, Dias OM, Pereira DAS, Pimenta SP, Kairalla RA, Carvalho CRR. Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):129–35.PubMed
16.
go back to reference Nascimento ECTD, Baldi BG, Mariani AW, Annoni R, Kairalla RA, Pimenta SP, da Silva LFF, Carvalho CRR, Dolhnikoff M. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir Res. 2018;19(1):83.CrossRefPubMedPubMedCentral Nascimento ECTD, Baldi BG, Mariani AW, Annoni R, Kairalla RA, Pimenta SP, da Silva LFF, Carvalho CRR, Dolhnikoff M. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir Res. 2018;19(1):83.CrossRefPubMedPubMedCentral
17.
go back to reference Miller S, Stewart ID, Clements D, Soomro I, Babaei-Jadidi R, Johnson SR. Evolution of lung pathology in lymphangioleiomyomatosis: associations with Disease course and treatment response. J Pathol Clin Res. 2020;6(3):215–26.CrossRefPubMedPubMedCentral Miller S, Stewart ID, Clements D, Soomro I, Babaei-Jadidi R, Johnson SR. Evolution of lung pathology in lymphangioleiomyomatosis: associations with Disease course and treatment response. J Pathol Clin Res. 2020;6(3):215–26.CrossRefPubMedPubMedCentral
18.
go back to reference Sobonya RE, Quan SF, Fleishman JS. Pulmonary lymphangioleiomyomatosis: quantitative analysis of lesions producing airflow limitation. Hum Pathol. 1985;16:1122–8.CrossRefPubMed Sobonya RE, Quan SF, Fleishman JS. Pulmonary lymphangioleiomyomatosis: quantitative analysis of lesions producing airflow limitation. Hum Pathol. 1985;16:1122–8.CrossRefPubMed
19.
go back to reference Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and Impairment of Gas Exchange as predictors of Outcome in Lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2001;164(6):1072–6.CrossRefPubMed Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and Impairment of Gas Exchange as predictors of Outcome in Lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2001;164(6):1072–6.CrossRefPubMed
20.
go back to reference Hayashi T, Kumasaka T, Mitani K, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. Hum Pathol. 2016;50:34–42.CrossRefPubMed Hayashi T, Kumasaka T, Mitani K, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. Hum Pathol. 2016;50:34–42.CrossRefPubMed
21.
go back to reference Verleden SE, Vanstapel A, Sadeleer LD, et al. Quantitative analysis of airway obstruction in lymphangioleiomyomatosis. Europ Resp J. 2020;56(1):1901965.CrossRef Verleden SE, Vanstapel A, Sadeleer LD, et al. Quantitative analysis of airway obstruction in lymphangioleiomyomatosis. Europ Resp J. 2020;56(1):1901965.CrossRef
22.
go back to reference Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para testes de função pulmonar. J Pneumol. 2002;28(suppl 3):1–S238. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para testes de função pulmonar. J Pneumol. 2002;28(suppl 3):1–S238.
23.
go back to reference Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397–406.CrossRefPubMed Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397–406.CrossRefPubMed
24.
go back to reference Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res. 1999;32(6):703–17.CrossRefPubMed Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res. 1999;32(6):703–17.CrossRefPubMed
25.
go back to reference Neder JA, Andreoni S, Peres C, Nery LE. Reference values for lung function tests. III. Carbon Monoxide diffusing capacity (transfer factor). Braz J Med Biol Res. 1999;32(6):729–37.CrossRefPubMed Neder JA, Andreoni S, Peres C, Nery LE. Reference values for lung function tests. III. Carbon Monoxide diffusing capacity (transfer factor). Braz J Med Biol Res. 1999;32(6):729–37.CrossRefPubMed
26.
go back to reference Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25(4):479–84.CrossRefPubMed Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25(4):479–84.CrossRefPubMed
27.
go back to reference Grzegorek I, Lenze D, Chabowski M, Janczak D, Szolkowska M, Langfort R, Szuba A, Dziegiel P. Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis. Anticancer Res. 2015;35(6):3353–60.PubMed Grzegorek I, Lenze D, Chabowski M, Janczak D, Szolkowska M, Langfort R, Szuba A, Dziegiel P. Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis. Anticancer Res. 2015;35(6):3353–60.PubMed
28.
go back to reference Sathirareuangchai S, Weon JL, Tintle S, Batra K, Yan SX, Torrealba JR. Recurrent lymphangioleiomyomatosis in a lung allograft with COVID-19: autopsy case report and literature review. Surg Exp Pathol. 2001; 4(13). Sathirareuangchai S, Weon JL, Tintle S, Batra K, Yan SX, Torrealba JR. Recurrent lymphangioleiomyomatosis in a lung allograft with COVID-19: autopsy case report and literature review. Surg Exp Pathol. 2001; 4(13).
29.
go back to reference James AL, Green FH, Abramson MJ, Bai TR, Dolhnikoff M, Mauad T, McKay KO, Elliot JG. Airway basement membrane perimeter distensibility and airway smooth muscle area in asthma. J Appl Physiol (1985). 2008; Jun;104(6):1703-8. James AL, Green FH, Abramson MJ, Bai TR, Dolhnikoff M, Mauad T, McKay KO, Elliot JG. Airway basement membrane perimeter distensibility and airway smooth muscle area in asthma. J Appl Physiol (1985). 2008; Jun;104(6):1703-8.
30.
go back to reference Matsushita MM, da Silva LF, dos Santos MA, Fernezlian S, Schrumpf JA, Roughley P, Hiemstra PS, Saldiva PH, Mauad T, Dolhnikoff M. Airway proteoglycans are differentially altered in fatal Asthma. J Pathol. 2005;207(1):102–10.CrossRef Matsushita MM, da Silva LF, dos Santos MA, Fernezlian S, Schrumpf JA, Roughley P, Hiemstra PS, Saldiva PH, Mauad T, Dolhnikoff M. Airway proteoglycans are differentially altered in fatal Asthma. J Pathol. 2005;207(1):102–10.CrossRef
31.
go back to reference James AL, Hogg JC, Dunn LA, Paré PD. The Use of the Internal Perimeter to compare Airway size and to calculate smooth muscle shortening. Am Rev Respir Dis. 1988;138(1):136–9.CrossRefPubMed James AL, Hogg JC, Dunn LA, Paré PD. The Use of the Internal Perimeter to compare Airway size and to calculate smooth muscle shortening. Am Rev Respir Dis. 1988;138(1):136–9.CrossRefPubMed
32.
go back to reference Evans SE, Colby TV, Ryu JH, Limper AH. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. Chest. 2004;25(3):1063–70.CrossRef Evans SE, Colby TV, Ryu JH, Limper AH. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. Chest. 2004;25(3):1063–70.CrossRef
Metadata
Title
Small airways morphological alterations associated with functional impairment in lymphangioleiomyomatosis
Authors
Lígia Pelosi Mendonça
Natalia de Souza Xavier Costa
Ellen Caroline Toledo do Nascimento
Martina Rodrigues de Oliveira
Carlos Roberto Ribeiro de Carvalho
Bruno Guedes Baldi
Marisa Dolhnikoff
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-023-02837-2

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.